Breaking News, Collaborations & Alliances

LSKB, Hengrui Enter Clinical Collaboration

To evaluate the safety & efficacy of LSKB's rivoceranib, known as apatinib or Aitan® in China with Hengrui's camrelizumab

LSK BioPharma and Jiangsu Hengrui Medicine, Co., Ltd.  announced that the companies have entered into a global clinical collaboration in patients with advanced hepatocellular carcinoma (HCC), evaluating the safety and efficacy of LSKB’s rivoceranib, also known as apatinib or Aitan® (brand name) in China, a selective and potent VEGFR-2 inhibitor, in combination with Hengrui’s camrelizumab (SHR-1210), a humanized anti-PD-1 monoclonal antibody currently under NDA review in China for cla...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters